What we're reading, January 13, 2016: at a recent healthcare investor conference pharmaceutical company executives showed no concern over public outrage of rising drug prices; the American Hospital Association urges MedPAC withdraw 340B payment proposal; and California lawmaker reintroduces "right-to-try" bill.
Pharmaceutical executives brushed off public outrage over the high cost of drugs during presentations at the 34th annual JP Morgan Healthcare conference in San Francisco. STAT reported that Gregg Alton, the executive vice president for corporate and medical affairs at Gilead Sciences, said he sleeps quite well when he was asked how he lives with himself. An executive at the industry group BIO called public anger at drug companies “an abomination” and Gilead’s president said drug pricing concerns aren’t a real issue but a “campaign issue.”
The American Hospital Association has written to the Medicare Payment Advisory Commission (MedPAC) to urge it to withdraw recommendations to reduce drug payments to hospitals participating in the 340B Drug Pricing Program. According to the letter, the recommendation penalizes certain hospitals for being able to obtain discounts. MedPAC is expected to vote on the payment proposal later this week.
Although California Governor Jerry Brown rejected last year a bill that would let terminally patients access experimental drugs, a lawmaker intends to reintroduce the legislation. The proposal would let patients with life-threatening diseases obtain recommendation from 2 doctors so they could try drugs that haven’t yet been approved by the FDA, according to LA Times.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen